Ensayos clínicos

8.676 ensayos encontrados

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to Assess the Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

INTERVENTIONALInicio: 25 de jun de 2024ID: NCT06463587

ReclutandoFase 3ClinicalTrials.gov

A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

INTERVENTIONALInicio: 28 de feb de 2025ID: NCT06855498

ReclutandoFase 2ClinicalTrials.gov

Efficacy, Safety and Pharmacokinetics of NNC0519-0130 Once Weekly s.c. Versussemaglutide 1.0 mg and Placebo in People With Chronic Kidney Disease, With or Without Type 2 Diabetes, and With Overweight or Obesity: a Proof-of-concept and Dose-finding Study

INTERVENTIONALInicio: 2 de dic de 2024ID: NCT06717698

ReclutandoClinicalTrials.gov

SMASH: Study to Evaluate the Clinical Efficacy of an Extensively Hydrolysed Infant Formula With Synbiotics and a Human Milk Oligosaccharide (HMO) in Infants With Cow's Milk Protein Allergy (CMPA)

OBSERVATIONALInicio: 7 de feb de 2025ID: NCT07342621

ReclutandoFase 3ClinicalTrials.gov

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

INTERVENTIONALInicio: 15 de may de 2025ID: NCT06993792

ReclutandoFase 3ClinicalTrials.gov

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)

INTERVENTIONALInicio: 3 de dic de 2024ID: NCT06685757

ReclutandoFase 2ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants With PPF

INTERVENTIONALInicio: 3 de abr de 2024ID: NCT06329401

ReclutandoFase 4ClinicalTrials.gov

Switch to Dolutegravir Plus Lamivudine Dual-therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)

INTERVENTIONALInicio: 31 de jul de 2025ID: NCT06967753

ReclutandoClinicalTrials.gov

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

OBSERVATIONALInicio: 1 de jul de 2012ID: NCT01574053

ReclutandoClinicalTrials.gov

Prospective, Observational Study in Participants With Active Systemic Lupus Erythematosus (SLE) (Including Lupus Nephritis) With Inadequate Response to Glucocorticoids and At Least 2 Immunosuppressants

OBSERVATIONALInicio: 8 de oct de 2025ID: NCT07175285

ReclutandoFase 2ClinicalTrials.gov

A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastic Breast Cancer After Progression on Previous Endocrine Therapy (LITESPARK-029)

INTERVENTIONALInicio: 27 de nov de 2024ID: NCT06428396

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia

INTERVENTIONALInicio: 11 de nov de 2025ID: NCT07216482

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult Participants With Active IgG4-related Disease

INTERVENTIONALInicio: 26 de sept de 2025ID: NCT07190196

ReclutandoFase 3ClinicalTrials.gov

Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT

INTERVENTIONALInicio: 16 de jun de 2022ID: NCT05429632

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Multi-country, Randomized, Placebo-controlled, Double-blinded Trial to Assess the Efficacy and Safety of Tecovirimat Antiviral Treatment for Patients With Monkeypox Virus Disease

INTERVENTIONALInicio: 3 de mar de 2023ID: NCT05597735

ReclutandoFase 3ClinicalTrials.gov

Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab

INTERVENTIONALInicio: 15 de mar de 2023ID: NCT05445778

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

INTERVENTIONALInicio: 23 de nov de 2023ID: NCT06103864

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 Years of Age)

INTERVENTIONALInicio: 29 de ene de 2026ID: NCT07288567

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)

INTERVENTIONALInicio: 6 de dic de 2023ID: NCT06077760

ReclutandoFase 3ClinicalTrials.gov

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients With Primary IgA Nephropathy at High Risk of Progression

INTERVENTIONALInicio: 8 de ago de 2023ID: NCT05797610